JP7350313B2 - 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 - Google Patents

抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 Download PDF

Info

Publication number
JP7350313B2
JP7350313B2 JP2019553163A JP2019553163A JP7350313B2 JP 7350313 B2 JP7350313 B2 JP 7350313B2 JP 2019553163 A JP2019553163 A JP 2019553163A JP 2019553163 A JP2019553163 A JP 2019553163A JP 7350313 B2 JP7350313 B2 JP 7350313B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequences
fragment
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502271A5 (enExample
JP2020502271A (ja
Inventor
ホン レン，
スコット マイケル ロニング，
ネルス エリック ペダーソン，
クラリサ リコヴァ，
アレクサンドル トカチェフ，
ティンレイ グー，
Original Assignee
ブルーフィン バイオメディシン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブルーフィン バイオメディシン， インコーポレイテッド filed Critical ブルーフィン バイオメディシン， インコーポレイテッド
Publication of JP2020502271A publication Critical patent/JP2020502271A/ja
Publication of JP2020502271A5 publication Critical patent/JP2020502271A5/ja
Priority to JP2022075922A priority Critical patent/JP7401126B2/ja
Application granted granted Critical
Publication of JP7350313B2 publication Critical patent/JP7350313B2/ja
Priority to JP2023203139A priority patent/JP2024026234A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019553163A 2016-12-16 2017-12-15 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 Active JP7350313B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022075922A JP7401126B2 (ja) 2016-12-16 2022-05-02 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP2023203139A JP2024026234A (ja) 2016-12-16 2023-11-30 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662435509P 2016-12-16 2016-12-16
US62/435,509 2016-12-16
US201762488445P 2017-04-21 2017-04-21
US62/488,445 2017-04-21
US201762588516P 2017-11-20 2017-11-20
US62/588,516 2017-11-20
PCT/US2017/066661 WO2018112334A1 (en) 2016-12-16 2017-12-15 Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075922A Division JP7401126B2 (ja) 2016-12-16 2022-05-02 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法

Publications (3)

Publication Number Publication Date
JP2020502271A JP2020502271A (ja) 2020-01-23
JP2020502271A5 JP2020502271A5 (enExample) 2021-02-04
JP7350313B2 true JP7350313B2 (ja) 2023-09-26

Family

ID=62559349

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019553163A Active JP7350313B2 (ja) 2016-12-16 2017-12-15 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP2022075922A Active JP7401126B2 (ja) 2016-12-16 2022-05-02 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP2023203139A Pending JP2024026234A (ja) 2016-12-16 2023-11-30 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022075922A Active JP7401126B2 (ja) 2016-12-16 2022-05-02 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP2023203139A Pending JP2024026234A (ja) 2016-12-16 2023-11-30 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法

Country Status (7)

Country Link
US (4) US11702481B2 (enExample)
EP (1) EP3554544A4 (enExample)
JP (3) JP7350313B2 (enExample)
CN (2) CN110234348B (enExample)
CA (1) CA3047115A1 (enExample)
MA (1) MA50134A (enExample)
WO (1) WO2018112334A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP7440509B2 (ja) * 2018-11-09 2024-02-28 ベス イスラエル デアコネス メディカル センター Ｃｄｃｐ１－標的化療法
WO2020153467A1 (ja) * 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
CA3128438A1 (en) * 2019-02-01 2020-08-06 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Methods of treating castrate-resistant prostate cancer
EP4055058A4 (en) * 2019-11-06 2023-12-06 Commonwealth Scientific and Industrial Research Organisation BINDING OF PROTEINS TO THE DOMAIN CONTAINING PROTEIN (CDCP1)
US20230050380A1 (en) 2019-12-27 2023-02-16 Chiome Bioscience Inc. Anti-cdcp1 antibody
US20240376224A1 (en) * 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240073008A (ko) * 2021-09-03 2024-05-24 노바록 바이오테라퓨틱스 리미티드 Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질
LU500787B1 (en) 2021-10-26 2023-04-27 Univ Hamburg Eppendorf Uke Isolation and detection of cdcp1 positive circulating tumor cells
CA3259098A1 (en) * 2022-06-20 2025-04-18 Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. ANTIBODIES AND THEIR USES
JP2025524727A (ja) 2022-07-15 2025-07-30 フィアン セラピューティクス エルティーディー Ｃｄｃｐ１と結合する抗体薬物複合体及びその使用
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도
KR20250134734A (ko) * 2022-12-16 2025-09-11 페온 테라퓨틱스 리미티드 Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
WO2025137236A1 (en) * 2023-12-21 2025-06-26 Nextcure, Inc. Compositions and methods for modulating cdcp1 mediated signal transduction
WO2025237395A1 (en) * 2024-05-17 2025-11-20 TJ Biopharma (Shanghai) Co., Ltd. Anti-cdcp1 constructs and uses thereof
WO2025252137A1 (zh) * 2024-06-06 2025-12-11 荣昌生物制药(烟台)股份有限公司 一种抗体药物偶联物
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007112734A (ja) 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
JP2011046712A (ja) 2003-02-19 2011-03-10 Novartis Ag 転移ヒト腫瘍細胞で発現される糖タンパク質抗原ｓｉｍａ１３５
JP2013502905A (ja) 2009-08-28 2013-01-31 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療のためのｃｄｃｐ１に対する抗体
JP2013502904A (ja) 2009-08-28 2013-01-31 ロシュ グリクアート アーゲー ヒト化抗ｃｄｃｐ１抗体
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US319A (en) 1837-07-31 Improvement in machines for breaking and dressing hemp and flax
US8236A (en) 1851-07-22 Hanging cakriage-body
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US4434150A (en) 1981-10-19 1984-02-28 Ortho Diagnostic Systems, Inc. Immunological reagents employing polymeric backbone possessing reactive functional groups
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
DE69232706T2 (de) 1991-05-01 2002-11-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994016729A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Targeted nitric oxide pathway or nitric oxide synthase modulation
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
IT1282692B1 (it) 1996-02-27 1998-03-31 San Raffaele Centro Fond Citochine modificate per l'uso in terapia
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2001503193A (ja) 1996-10-28 2001-03-06 エービービー パワー システムズ アクチボラゲット 高圧直流伝送システムの地中電極
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
PL336231A1 (en) 1997-02-13 2000-06-19 Bone Care International System for aimed therapeutic delivery of vitamin d compounds
EP0973540B1 (en) 1997-02-25 2005-11-02 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
AU9692498A (en) 1997-10-10 1999-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Complex of biotinylated viral vector and ligand for targeted gene delivery
WO1999066027A1 (en) 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
CN1269087C (zh) 1999-07-31 2006-08-09 朴奎珍 使用数字音频和字幕数据的学习方法和装置
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
WO2001090198A1 (en) 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
MXPA03000105A (es) 2000-06-28 2004-09-13 Glycofi Inc Metodo para producir glicoproteinas modificadas.
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
WO2003093793A2 (en) 2002-05-01 2003-11-13 Trellis Bioscience, Inc. Binary or polynary targeting and uses thereof
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2004013093A2 (en) 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP2289559B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080166375A1 (en) 2003-05-06 2008-07-10 The Government Of The United States Of America, As Rep. By The Secretary Of Health And Human Service Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells
WO2005020883A2 (en) 2003-05-08 2005-03-10 Immunogen, Inc. Methods for the production of ansamitocins
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EA009285B1 (ru) 2003-05-14 2007-12-28 Иммуноджен, Инк. Композиция конъюгированного лекарственного средства
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PT1651162E (pt) 2003-05-20 2016-02-22 Immunogen Inc Agentes citotóxicos melhorados compreendendo novos maitansinóides
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005052129A2 (en) 2003-11-25 2005-06-09 Anjin Corporation Diptheria toxin variant
WO2005070457A1 (en) 2004-01-23 2005-08-04 Seattle Genetics, Inc. Melphalan prodrugs
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP2392586A1 (en) 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Binding peptidomimetics and uses of the same
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US20050226882A1 (en) 2004-04-08 2005-10-13 Awdalla Essam T Method and multicomponent conjugates for treating cancer
CN104611245A (zh) 2004-04-15 2015-05-13 格利科菲公司 在低等真核生物中产生半乳糖基化糖蛋白
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
JP4193771B2 (ja) 2004-07-27 2008-12-10 セイコーエプソン株式会社 階調電圧発生回路及び駆動回路
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
EP1695717A1 (en) 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
AU2006269940C1 (en) 2005-07-18 2013-11-07 Seagen Inc. Beta-glucuronide-linker drug conjugates
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7411063B2 (en) 2005-11-08 2008-08-12 Immunogen, Inc. Process for preparation of maytansinol
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
CA2690973A1 (en) 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7598028B2 (en) 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
JP5564266B2 (ja) 2007-02-16 2014-07-30 メリマック ファーマシューティカルズ インコーポレーティッド Ｅｒｂｂ３に対する抗体およびその使用
TW200900078A (en) 2007-02-23 2009-01-01 Baylor Res Inst Activation of human antigen-presenting cells through CLEC-6
CA2715919C (en) 2007-02-23 2020-04-21 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
DK2447719T3 (en) 2007-02-26 2016-10-10 Oxford Biotherapeutics Ltd proteins
CA2687395C (en) 2007-05-03 2017-07-11 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
AR069979A1 (es) 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2009134952A2 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
US20100233154A1 (en) 2008-10-08 2010-09-16 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
US8394818B2 (en) 2008-10-17 2013-03-12 Dana-Farber Cancer Institute, Inc. Soluble mTOR complexes and modulators thereof
JP5977522B2 (ja) 2009-02-05 2016-08-24 イミュノジェン・インコーポレーテッド 新規ベンゾジアゼピン誘導体
SG174367A1 (en) 2009-03-23 2011-10-28 Quark Pharmaceuticals Inc Compounds compositions and methods of treating cancer and fibrotic diseases
WO2010126551A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers
WO2010126552A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
RU2015128833A (ru) 2009-05-06 2015-11-10 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
DE102009026075A1 (de) 2009-06-30 2011-01-05 Röhm Gmbh Bohrvorrichtung
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011057216A1 (en) 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
GB0919751D0 (en) 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
KR20240052894A (ko) 2010-02-24 2024-04-23 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
EP2558127B1 (en) 2010-04-15 2022-01-19 Seagen Inc. Targeted pyrrolobenzodiazepine conjugates
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
MX369679B (es) 2010-09-29 2019-11-15 Agensys Inc Conjugados de anticuerpo fármaco (adc) que enlazan a proteínas 191p4d12.
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
CA2815363C (en) 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
CN106349254A (zh) 2010-11-03 2017-01-25 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
ES2702926T3 (es) 2010-12-09 2019-03-06 Immunogen Inc Métodos para la preparación de agentes de reticulación cargados
TWI617555B (zh) 2011-02-15 2018-03-11 免疫原公司 細胞毒性苯并二氮呯衍生物
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
CA2837892A1 (en) * 2011-06-14 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tem8 antibodies, conjugates thereof, and their use
MX350954B (es) 2011-06-21 2017-09-26 Immunogen Inc Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
US9387259B2 (en) 2011-10-14 2016-07-12 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
DK2794658T3 (en) 2011-12-19 2017-06-19 Synimmune Gmbh BISPECIFIC ANTIBODY MOLECULE
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
CA2873097A1 (en) 2012-05-11 2013-11-14 Todd M. Hansen Pyridazine and pyridine derivatives as nampt inhibitors
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
SI2900676T1 (sl) 2012-09-26 2019-04-30 Immunogen, Inc. Izboljšana metoda za aciliranje majtanzinola
WO2014159010A1 (en) 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
CA2947048C (en) 2014-06-11 2023-10-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
CN107209187B (zh) 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法
RU2017110068A (ru) 2014-09-03 2018-10-03 Иммуноджен, Инк. Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
KR102349475B1 (ko) 2015-04-13 2022-01-11 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046712A (ja) 2003-02-19 2011-03-10 Novartis Ag 転移ヒト腫瘍細胞で発現される糖タンパク質抗原ｓｉｍａ１３５
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
JP2007112734A (ja) 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
JP2013502905A (ja) 2009-08-28 2013-01-31 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療のためのｃｄｃｐ１に対する抗体
JP2013502904A (ja) 2009-08-28 2013-01-31 ロシュ グリクアート アーゲー ヒト化抗ｃｄｃｐ１抗体
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane

Also Published As

Publication number Publication date
US12138313B2 (en) 2024-11-12
CN110234348B (zh) 2024-06-25
CN118562004A (zh) 2024-08-30
US20240287203A1 (en) 2024-08-29
WO2018112334A1 (en) 2018-06-21
JP2020502271A (ja) 2020-01-23
US12491256B2 (en) 2025-12-09
CA3047115A1 (en) 2018-06-21
EP3554544A4 (en) 2020-07-29
CN110234348A (zh) 2019-09-13
JP2024026234A (ja) 2024-02-28
US12138314B2 (en) 2024-11-12
MA50134A (fr) 2020-07-29
JP2022101693A (ja) 2022-07-06
US11702481B2 (en) 2023-07-18
JP7401126B2 (ja) 2023-12-19
EP3554544A1 (en) 2019-10-23
US20240270868A1 (en) 2024-08-15
US20240084032A1 (en) 2024-03-14
US20200181281A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
JP7401126B2 (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US12350347B2 (en) Nucleic acids encoding anti-IL1RAP antibodies and their uses
JP7522477B2 (ja) 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
US12473358B2 (en) Anti-TMEFF1 antibodies and antibody drug conjugates
US20250319180A1 (en) Anti-ly6h antibodies and antibody drug conjugates
JP7803577B2 (ja) 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
HK40114669A (zh) 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
HK40014209A (en) Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
HK40014209B (zh) 抗-含cub结构域蛋白1 (cdcp1)抗体、抗体药物缀合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7350313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150